

**Anti-virulence strategy of novel dehydroabiatic acid derivatives:
Design, synthesis, and antibacterial evaluation**

Puying Qi, Na Wang, Taihong Zhang, Yumei Feng, Xiang Zhou *, Dan Zeng, Jiao Meng,
Liwei Liu, Linhong Jin, Song Yang *

National Key Laboratory of Green Pesticide, Key Laboratory of Green Pesticide and
Agricultural Bioengineering, Ministry of Education, Center for R&D of Fine Chemicals
of Guizhou University, Guiyang 550025, China

* Corresponding author.

E-mail: zhoux1534@163.com or xiangzhou@gzu.edu.cn (X.Z.);

Content

1. Experimental section	3
1.1 <i>In vitro</i> antibacterial bioassay (turbidimeter test)	3
1.2 <i>In vivo</i> bioassay rice bacterial leaf blight	4
1.3 Synthesis for intermediates and target compounds	4
1.3.1 General synthetic procedure for the intermediate 1	4
1.3.2 General synthetic procedures for the target compounds 2a-2p	5
1.4 Table S1. Antibacterial bioactivity of cyclohexanecarboxylic acid derivatives against the phytopathogenic bacteria <i>Xoo</i> and <i>Xac</i> in vitro.	5
1.5 Table S2. The absorbance at 595 nm of compound 2b against bacteria <i>Xoo</i> at the concentration of 0 and 5.4 $\mu\text{g mL}^{-1}$	5
1.6 Table S3. The logS and logP of resulting compounds.	5
1.7 Table S4. The MIC value of compound 2b.	6
2. ^1H NMR, ^{13}C NMR, ^{19}F NMR and HRMS Spectra (Figure S1-S56)	6
3. Figure S57. The physicochemical properties of resulting compounds.	47

1. Experimental section

1.1 *In vitro* antibacterial bioassay (turbidimeter test)

In our study, all the synthesized target compounds were evaluated for their antibacterial activities against *Xoo*, *Psa*, and *Xac* by the turbidimeter test *in vitro*.¹ Dimethylsulfoxide in sterile distilled water served as a blank control, Thiodiazole Copper served as positive controls. Approximately 40 μL of solvent NB (1.5 g beef extract, 2.5 g peptone, 0.5 g yeast powder, 5.0 g glucose, and 500 mL distilled water; pH = 7.0–7.2) containing *Xoo* (*Psa* or *Xac*), incubated on the phase of logarithmic growth, was added to 5 mL of solvent NB containing different concentrations of the test compounds and positive control, such as 100, 50 $\mu\text{g/mL}$ (for preliminary bioassays), 20, 10, 5, 2.5, 1.25 $\mu\text{g mL}^{-1}$ or 10, 5, 2.5, 1.25, 0.625 $\mu\text{g mL}^{-1}$ (depending on the bioactivity of different compounds, the concentrations were chosen in two times decline trend to make sure the EC₅₀ values are inside the concentration ranges tested). The inoculated test tubes were incubated at 28 ± 1 °C and continuously shaken at 180 rpm for 24–48 h until the bacteria were incubated on the logarithmic growth phase. The growth of the cultures was monitored on a microplate reader by measuring the optical density at 595 nm (OD₅₉₅) given by turbidity corrected values = OD_{bacterial wilt} – OD_{no bacterial wilt}, and the inhibition rate I was calculated by $I = (C - T)/C \times 100\%$. C is the corrected turbidity values of bacterial growth on untreated NB (blank control), and T is the corrected turbidity values of bacterial growth on treated NB. By using the SPSS 20.0 software and the obtained inhibition rates at different concentrations, a regression equation was provided. The results of antibacterial activities (expressed by EC₅₀) against *Xoo*, *Psa*, and *Xac* were

calculated from the equation and the value was within the concentration ranges. The experiment was repeated three times.

1.2 *In vivo* bioassay rice bacterial leaf blight

In vivo antibacterial activities of compound **2b** against rice bacterial leaf blight were performed based on our reported method. Thiodiazole copper (TC) were used as the positive controls, and the rice plants (variety Xiangliangyou 900) grown in the maximum leaf stage were used in this experiment. For the protective activity, different adjuvants were added into a compound **2b** solution at 200 $\mu\text{g mL}^{-1}$ to get a mixture that included organic silicone, organic fluorine, and orange peel essential oil with a dose of 0.1% (v/v), respectively. Then the mixture was evenly sprayed on the rice leaves; 24 h after spraying, *Xoo* cell solution ($\text{OD}_{595} = 0.8\text{--}1.0$) was inoculated on the rice leaves. Control efficiency I (%) = $(C - T) / C \times 100$.

1.3 Synthesis for intermediates and target compounds





1.3.1 General synthetic procedure for the intermediate 1

Epibromohydrin (1.2 mmol) and dehydroabietic acid (1.0 mmol) were dissolved in the 5 mL anhydrous DMF solvent, which was added into 15 mL pressure-resistant reaction tube contained K_2CO_3 (1.2 mmol) protected by Ar atmosphere. After stirring the mixture at 60 °C for 8 hours, 30 mL ethyl acetate was added into the mixture. The organic layer was washed 3 times by 45mL saturated NH_4Cl solution, water, brine, dried with sodium sulfate, filtered, and followed by the removal of the solvent under vacuum. The pure intermediate could be obtained by column chromatography using the eluent (PE:EA, V:V = 5:1).

1.3.2 General synthetic procedures for the target compounds 2a-2p

Generally, to a 15 mL pressure-resistant reaction tube, compound **1** (1.12 mmol) were dissolved in 5 mL dry isopropanol, then corresponding amines (2.24 mmol) were added and heated to 40 °C for 6 hours. After that, the removal of the solvent under vacuum. Finally, the crude residue was further purified by column chromatography on a silica gel using CH₂Cl₂ and MeOH (200:1-20:1, V/V) as the eluent to afford the desired product **2a**. The synthesis of all compounds (**2b-2p**) was carried out as the synthetic protocol of **2a**.

1.4 Table S1. Antibacterial bioactivity of cyclohexanecarboxylic acid derivatives against the phytopathogenic bacteria *Xoo* and *Xac* in vitro.

Compounds	Inhibition ratio (%)			
	<i>Xoo</i>		<i>Xac</i>	
	100 µg mL ⁻¹	50 µg mL ⁻¹	100 µg mL ⁻¹	50 µg mL ⁻¹
	13.1±2.5	0	0	0
	0	0	0	0
	16.8±4.9	11.5±4.5	0	0
	0	0	0	0

1.5 Table S2. The absorbance at 595 nm of compound 2b against bacteria *Xoo* at the concentration of 0 and 5.4 µg mL⁻¹.

Treatment (µg mL ⁻¹)	OD ₅₉₅
0	0.466±0.018
5.4	0.462±0.008

1.6 Table S3. The logS and logP of resulting compounds.

Compds	logS	logP
--------	------	------

2a	-4.512	4.310
2b	-4.649	4.577
2c	-4.977	5.255
2d	-5.326	5.783
2e	-5.465	5.943
2f	-5.414	5.874
2g	-5.969	6.444
2h	-5.097	5.431
2i	-5.107	5.398
2j	-5.100	5.444
2k	-5.291	5.618
2l	-5.379	5.657
2m	-5.361	5.291
2n	-5.367	5.285
2o	-4.769	4.031
2p	-4.723	4.358

logS: log of the aqueous solubility, Optimal: -4~0.5 log mol L⁻¹; logP: log of the octanol/water partition coefficient, Optimal: 0~3.

1.7 Table S4. The MIC value of compound 2b.

Compound	MIC
2b	10.8 µg mL ⁻¹

2. ¹H NMR, ¹³C NMR, ¹⁹F NMR and HRMS Spectra (Figure S1-S56)

Dehydroabietic acid (DAA)

¹H NMR (500 MHz, DMSO-*d*₆) δ 12.17 (s, 1H, -COOH), 7.15 (d, *J* = 8.0 Hz, 1H, phenyl-H), 6.97 (d, *J* = 8.0 Hz, 1H, phenyl-H), 6.84 (s, 1H, phenyl-H), 2.85 – 2.75 (m, 2H, phenyl-cyclohexane-CH₂), 2.29 (d, *J* = 13.3 Hz, 1H, phenyl-cyclohexane-CH-CH₂),

2.02 (dd, $J = 12.4, 2.0$ Hz, 1H, $\underline{\text{CH}}(\text{CH}_3)_2$), 1.81 – 1.69 (m, 2H, cyclohexane- $\underline{\text{CH}_2}$), 1.68 – 1.60 (m, 2H, cyclohexane- $\underline{\text{CH}_2}$), 1.56 (m, 1H, phenyl-cyclohexane-1/2 $\underline{\text{CH}_2}$), 1.39 (m, 1H, phenyl-cyclohexane-1/2 $\underline{\text{CH}_2}$), 1.33 – 1.21 (m, 2H, cyclohexane- $\text{CH}_2\text{CH}_2\text{CH}_2$), 1.16 (d, $J = 1.0$ Hz, 6H, $\text{CH}(\underline{\text{CH}_3})_2$), 1.14 (s, 3H, CCH_3), 1.12 (s, 3H, CCH_3COOH). ^{13}C NMR (126 MHz, CDCl_3) δ 185.41, 146.78, 145.75, 134.74, 126.94, 124.16, 123.92, 47.47, 44.59, 40.43, 37.92, 36.89, 36.75, 33.49, 32.55, 30.04, 25.18, 24.02, 21.80, 18.57, 16.23.

3-propylene oxide-1- dehydroabietic acid ester (1)

A colorless oil liquid, yield 67.4%; ^1H NMR (400 MHz, CDCl_3) δ 7.10 (d, $J = 8.4$ Hz, 1H, phenyl-H), 6.93 (d, $J = 8.0$ Hz, 1H, phenyl-H), 6.82 (s, 1H, phenyl-H), 4.32 (ddd, $J = 31.6, 12.4, 6.4$ Hz, 1H, 1/2 $\text{COOCH}_2\text{CHCH}_2$), 3.86 (ddd, $J = 28.0, 12.3, 6.2$ Hz, 1H, 1/2 $\text{COOCH}_2\text{CHCH}_2$), 3.11 (ddd, $J = 10.0, 6.4, 3.2$ Hz, 1H, $\text{COOCH}_2\text{CHCH}_2$), 2.82 (m, 2H, phenyl-cyclohexane- $\underline{\text{CH}_2}$), 2.78 – 2.70 (m, 1H, 1/2 $\text{COOCH}_2\text{CHCH}_2$), 2.56 (dd, $J = 4.8, 2.8$ Hz, 1H, 1/2 $\text{COOCH}_2\text{CHCH}_2$), 2.22 (t, $J = 12.4$ Hz, 2H, $\text{CCHCH}_2 + \underline{\text{CH}}(\text{CH}_3)_2$), 1.84 – 1.53 (m, 6H, cyclohexane-3 $\underline{\text{CH}_2}$), 1.48 – 1.31 (m, 2H, phenyl-cyclohexane- $\underline{\text{CH}_2}$), 1.22 (s, 3H, CCH_3), 1.16 (s, 3H, CCH_3COO), 1.14 (s, 6H, $\text{CH}(\underline{\text{CH}_3})_2$). ^{13}C NMR (101 MHz, CDCl_3) δ 178.31, 146.74, 145.77, 134.68, 126.96, 124.22, 123.99, 65.13, 49.44, 47.83, 44.86, 44.64, 37.95, 36.98, 36.62, 33.49, 30.14, 25.23, 24.01, 21.83, 18.59, 16.53.

3-((4-*N*-methylpiperazine) amino)-2-hydroxypropyl-1-dehydroabietic acid ester (2a)

A colorless oil liquid, yield 57.0%; ^1H NMR (500 MHz, CDCl_3) δ 7.14 (d, $J = 8.0$ Hz, 1H, phenyl-H), 6.97 (d, $J = 6.0$ Hz, 1H, phenyl-H), 6.85 (d, $J = 5.0$ Hz, 1H, phenyl-H),

5.08 – 4.94 (m, CHOH), 4.19 – 3.93 (m, 1H, 1/2COOCH₂CHCH₂), 3.93 – 3.84 (m, 1H, COOCH₂CHCH₂), 3.77 – 3.65 (m, 1H, 1/2COOCH₂CHCH₂), 2.86 (dd, $J = 16.0, 3.5$ Hz, 2H, phenyl-cyclohexane-CH₂), 2.79 (dd, $J = 13.8, 6.9$ Hz, 1H, 1/2COOCH₂CHCH₂), 2.68 – 2.54 (m, 3H, 1/2COOCH₂CHCH₂ + CCHCH₂+CH(CH₃)₂), 2.37 (m, 4H, 2(NCH₂CH₂N)CH₃), 2.31 – 2.18 (m, 7H, 2(NCH₂CH₂N)CH₃ +(CH₂)₂NCH₃), 1.80 – 1.59 (m, 6H, cyclohexane-3CH₂), 1.51 – 1.38 (m, 2H, phenyl-cyclohexane-CH₂), 1.27 – 1.22 (m, 3H, CCH₃), 1.20 (s, 3H, CCH₃COO), 1.19 (s, 6H, CH(CH₃)₂). ¹³C NMR (126 MHz, CDCl₃) δ 178.61, 146.91, 145.77, 134.74, 126.97, 124.28, 124.01, 69.28, 66.73, 66.60, 65.12, 60.61, 60.38, 55.17, 55.11, 47.88, 46.06, 44.92, 37.99, 37.03, 36.71, 33.53, 30.19, 25.35, 24.09, 21.84, 18.66, 16.64. HRMS: m/z [M+H]⁺ calcd for C₂₈H₄₅N₂O₃:457.3425; found:457.3420.

3-((4-*N*-ethylpiperazine) amino)-2-hydroxypropyl-1-dehydroabietic acid ester ester (2b)

A colorless oil liquid, yield 75.1%; ¹H NMR (400 MHz, CDCl₃) δ 7.16 (d, $J = 8.4$ Hz, 1H, phenyl-H), 7.00 (d, $J = 8.4$ Hz, 1H, phenyl-H), 6.87 (s, 1H, phenyl-H), 4.18 (dd, $J = 11.4, 4.0$ Hz, 1H, 1/4COOCH₂CHCH₂), 4.13 – 4.04 (m, 1H, 1/2COOCH₂CHCH₂), 4.00 (dd, $J = 11.4, 5.6$ Hz, 1H, 1/2COOCH₂CHCH₂), 3.96 – 3.87 (m, 1H, COOCH₂CHCH₂), 2.96 – 2.85 (m, 2H, phenyl-cyclohexane-CH₂), 2.81 (dd, $J = 14.0, 7.2$ Hz, 1H, COOCH₂CHCH₂), 2.74 – 2.68 (m, 1H, COOCH₂CHCH₂), 2.73 – 2.56 (m, 2H, piperzine-NCH₂CH₃), 2.53 – 2.35 (m, 8H, piperzine-8H), 2.34 – 2.20 (m, 2H, CCHCH₂+CH(CH₃)₂), 1.90 – 1.63 (m, 6H, cyclohexane-CH₂CH₂CH₂), 1.55 – 1.40 (m, 2H, phenyl-cyclohexane-CH₂), 1.30 – 1.25 (m, 3H, CCH₃), 1.23 (s, 3H, CCH₃COO),

1.21 (s, 6H, CH(CH₃)₂), 1.08 (t, $J = 7.2$ Hz, 3H, piperzine-NCH₂CH₃). ¹³C NMR (101 MHz, CDCl₃) δ 178.51, 146.84, 145.69, 134.67, 126.89, 124.22, 123.94, 66.68, 66.55, 65.07, 60.39, 60.30, 52.81, 52.26, 47.80, 44.81, 37.94, 36.97, 36.65, 33.46, 30.14, 25.26, 24.02, 21.77, 18.60, 16.57, 11.98. HRMS: m/z [M+H]⁺ calcd for C₂₉H₄₇N₂O₃:471.3581; found:471.3578.

3-((4-*N*-tert butyl piperazine) amino-2-hydroxypropyl-1-dehydroabietic acid ester (2c)

A white solid, yield 61.7%, m. p. 96.3-97.5 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.14 (d, $J = 8.0$ Hz, 1H, phenyl-H), 6.97 (d, $J = 7.5$ Hz, 1H, phenyl-H), 6.85 (s, 1H, phenyl-H), 4.19 – 3.94 (m, 2H, COOCH₂CHCH₂), 3.89 (d, $J = 4.0$ Hz, 2H, COOCH₂CHCH₂), 2.89 (d, $J = 35.9$ Hz, 2H, phenyl-cyclohexane-CH₂CH₂), 2.79 (dt, $J = 13.3, 6.8$ Hz, 1H, 1/2COOCH₂CHCH₂), 2.68 (s, 1H, 1/2COOCH₂CHCH₂), 2.60 (d, $J = 16.5$ Hz, 4H, 2CH₂NC(CH₃)₃), 2.49 – 2.33 (m, 4H, 2CH₂CH₂NC(CH₃)₃), 2.25 (dd, $J = 21.0, 12.0$ Hz, 2H, CCHCH₂ + CH(CH₃)₂), 1.85 – 1.61 (m, 6H, cyclohexane-CH₂CH₂CH₂), 1.45 (m, 2H, phenyl-cyclohexane-CH₂CH₂), 1.26 (s, 3H, CCH₃CH₂), 1.20 (s, 3H, CCH₃COO), 1.19 (s, 6H, CH(CH₃)₂), 1.07 (s, 9H, C(CH₃)₃). ¹³C NMR (126 MHz, CDCl₃) δ 178.62, 146.91, 145.77, 134.75, 126.99, 124.28, 124.01, 66.76, 66.63, 65.12, 60.29, 60.22, 54.50, 53.64, 47.88, 45.77, 44.91, 44.86, 37.99, 37.03, 36.72, 33.53, 30.21, 30.18, 25.82, 25.34, 24.09, 21.84, 18.66, 16.63. HRMS: m/z [M+H]⁺ calcd for C₃₁H₅₁N₂O₃:499.3894; found:499.3891.

3-((4-*N*-phenylperazine) amino)-2-hydroxypropyl-1-dehydroabietic acid ester (2d)

A white solid, yield 55.0%, m. p. 102.1-103.6 °C; ¹H NMR (400 MHz, CDCl₃) δ 7.27

(dd, $J = 8.4, 7.6$ Hz, 2H, piperazine-NC(CH)₂(CH)₂CH), 7.17 (d, $J = 8.4$ Hz, 1H, DAA-phenyl-H), 7.00 (d, $J = 8.4$ Hz, 1H, DAA-phenyl-H), 6.93 (d, $J = 8.5$ Hz, 2H, piperazine-NC(CH)₂(CH)₂CH), 6.88 (t, $J = 6.0$ Hz, 2H, DAA-phenyl-1H + piperazine-NC(CH)₂(CH)₂CH), 4.21 (dd, $J = 11.2, 4.0$ Hz, 1/2H, 1/4 COOCH₂CHCH₂), 4.12 (m, 1H, 1/2H, 1/2COOCH₂CHCH₂), 4.05 (dd, $J = 12.4, 6.8$ Hz, 1/2H, 1/4COOCH₂CHCH₂), 4.03 – 3.97 (m, 1H, COOCH₂CHCH₂), 3.28– 3.19 (m, 4H, phenyl-N(CH₂)₂), 2.93 – 2.78 (m, 4H, phenyl-N(CH₂)₂(CH₂)₂), 2.68 – 2.59 (m, 2H, phenyl-cyclohexane-CH₂CH₂), 2.54 – 2.44 (m, 2H, COOCH₂CHCH₂), 2.35 – 2.20 (m, 2H, CCHCH₂ + CH(CH₃)₂), 1.85 – 1.64 (m, 6H, cyclohexane-CH₂CH₂CH₂), 1.52 – 1.41 (m, 2H, phenyl-cyclohexane-CH₂CH₂), 1.30 (s, 3H, CCH₃CH₂), 1.23 (s, 3H, CCH₃COO), 1.22 (d, $J = 1.6$ Hz, 6H, CH(CH₃)₂). **¹³C NMR (101 MHz, CDCl₃)** δ 178.56, 151.03, 146.85, 145.77, 134.67, 129.19, 126.92, 124.22, 123.97, 120.08, 116.25, 77.36, 77.04, 76.73, 66.59, 66.47, 65.13, 60.50, 60.42, 53.30, 49.15, 47.85, 44.90, 37.94, 36.99, 36.69, 33.47, 30.14, 29.73, 25.26, 24.01, 21.80, 18.60, 16.58. **HRMS:** m/z [M+H]⁺ calcd for C₃₃H₄₇N₂O₃:519.3581; found:519.3578.

3-((4-*N*-2-fluorophenylpiperazine) amino)-2-hydroxypropyl-1-dehydroabiatic acid ester (2e)

A yellow solid, yield 60.9%, m. p. 58.5-59.8 °C; **¹H NMR (500 MHz, CDCl₃)** δ 7.19 (d, $J = 8.0$ Hz, 1H, DAA-phenyl-H), 7.04 (m, 3H, DAA-phenyl-H + phenyl-NCCFCHCHCHCH), 6.98 – 6.92 (m, 2H, phenyl-NCCFCHCHCHCH), 6.90 (s, 1H, DAA-phenyl-H), 5.27 (s, 1H, OH), 4.23 (dd, $J = 11.4, 3.8$ Hz, 1/2H, 1/4COOCH₂CHCH₂), 4.17 – 4.10 (ddd, $J = 11.5, 6.0, 4.5$ Hz, 1H, 1/2COOCH₂CHCH₂),

4.05 (dd, $J = 11.0, 5.5$ Hz, 1/2H, 1/4COOCH₂CHCH₂), 3.98 (ddd, $J = 13.0, 9.5, 5.0$ Hz, 1H, COOCH₂CHCH₂), 3.20 – 3.05 (m, 4H, phenyl-piperazine-CFCN(CH₂)₂), 2.96 – 2.86 (m, 2H, phenyl-cyclohexane-CH₂), 2.85 – 2.76 (m, 2H, COOCH₂CHCH₂), 2.66 – 2.56 (m, 2H, phenyl-piperazine-CFCN(CH₂)₂CH₂), 2.52 – 2.44 (m, 2H, phenyl-piperazine-CFCN(CH₂)₂CH₂), 2.35 – 2.25 (m, 2H, CCH₂CH₂ + CH(CH₃)₂), 1.97 – 1.58 (m, 6H, cyclohexane-CH₂CH₂CH₂), 1.52 – 1.43 (m, 2H, phenyl-cyclohexane-CH₂), 1.30 (d, $J = 8.6$ Hz, 3H, CCH₃CH₂), 1.24 (s, 3H, CCH₃COO), 1.23 (s, 6H, CH(CH₃)₂). ¹³C NMR (126 MHz, CDCl₃) δ 178.65, 156.79, 154.83, 146.87, 145.83, 140.05 (d, ¹J_{C-F} = 8.6 Hz), 134.78, 127.03, 124.62, (d, ²J_{C-F} = 3.2 Hz), 124.33 (d, ³J_{C-F} = 32.0 Hz), 122.77 (d, ⁴J_{C-F} = 7.9 Hz), 119.06 (d, ⁵J_{C-F} = 2.4 Hz), 116.34 (d, ⁶J_{C-F} = 20.5 Hz), 66.75, 66.63, 65.23, 60.53, 60.45, 53.43, 50.68, 47.93, 44.98, 38.04, 37.08, 36.77, 33.58, 30.24, 25.39, 24.14, 21.90, 18.71, 16.70. ¹⁹F NMR (376 MHz, DMSO-*d*₆) δ -122.78. HRMS: m/z [M+H]⁺ calcd for C₃₃H₄₆N₂O₃F: 537.3487; found: 537.3485.

3-((4-*N*-4-fluorophenylperazine) amino)-2-hydroxypropyl-1-dehydroabietic acid ester (2f)

A pink solid, yield 83.5%, m. p. 90.4-91.3 °C; ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.15 (d, $J = 8.4$ Hz, 1H, DAA-phenyl-H), 7.02 (t, $J = 8.8$ Hz, 2H, piperazine-NC(CH₂)₂CF), 6.96 (d, $J = 8.1$ Hz, 1H, DAA-phenyl-H), 6.94 – 6.87 (m, 2H, piperazine-NC(CH₂)₂(CH)₂CF), 6.83 (s, 1H, DAA-phenyl-H), 4.85 (s, 1H, OH), 4.09 (dd, $J = 10.8, 4.0$ Hz, 1/2H, 1/4COOCH₂CHCH₂), 4.04 – 3.96 (m, 1H, 1/2COOCH₂CHCH₂), 3.92 (dd, $J = 10.8, 6.0$ Hz, 1/2H, 1/4COOCH₂CHCH₂), 3.86 (s, 1H, COOCH₂CHCH₂), 3.15 – 2.95 (m, 4H, phenyl-piperazine-N(CH₂)₂(CH₂)₂), 2.83 –

2.70 (m, 2H, COOCH₂CHCH₂), 2.63 – 2.51 (m, 4H, phenyl-piperazine-N(CH₂)₂(CH₂)₂), 2.43 – 2.33 (m, 2H, phenyl-cyclohexane-CH₂), 2.26 (d, *J* = 12.4 Hz, 1H, CH(CH₃)₂), 2.11 (d, *J* = 12.4 Hz, 1H, CCHCH₂), 1.84 – 1.47 (m, 6H, cyclohexane-CH₂CH₂CH₂), 1.40 – 1.26 (m, 2H, phenyl-cyclohexane-CH₂), 1.20 (s, 3H, CCH₃CH₂), 1.15 (s, 3H, CCH₃COO), 1.13 (d, *J* = 3.9 Hz, 6H, CH(CH₃)₂). **¹³C NMR (101 MHz, DMSO-*d*₆)** δ 177.98, 177.97, 157.60, 155.26, 148.38, 147.09, 145.54, 134.62, 126.91, 124.56, 124.20, 117.51 (¹*J*_{C-F} = 7.5 Hz), 115.78, 115.56, 66.38, 61.49, 53.86, 49.45, 47.54, 45.19, 45.07, 38.13, 36.97, 36.57, 33.36, 30.01, 25.38, 24.41, 24.36, 21.63, 18.59, 16.82, 16.80. **¹⁹F NMR (376 MHz, DMSO-*d*₆)** δ -125.70. **HRMS: *m/z* [M+H]⁺** calcd for C₃₃H₄₆N₂O₃F: 537.3487; found: 537.3485.

3-((4-*N*-3-chloro-5-trifluoro-2-pyridinyl)perazine amino)-2-hydroxypropyl-1-dehydroabietic acid ester (2g)

A yellow oil liquid, yield 63.9%; **¹H NMR (500 MHz, CDCl₃)** δ 8.38 (s, 1H, pyridine-H), 7.75 (d, *J* = 2.0 Hz, 1H, pyridine-H), 7.17 (d, *J* = 8.0 Hz, 1H, phenyl-H), 6.99 (d, *J* = 8.0 Hz, 1H, phenyl-H), 6.88 (s, 1H, phenyl-H), 5.28 (s, 1H, OH), 4.23 – 4.02 (m, 2H, COOCH₂CHCH₂), 3.97 (ddd, *J* = 13.0, 9.0, 4.5 Hz, 1H, COOCH₂CHCH₂), 3.52 (s, 4H, pyridine-2NCH₂CH₂), 2.93 – 2.85 (m, 2H, phenyl-cyclohexane-CH₂CH₂), 2.84 – 2.76 (m, 2H, COOCH₂CHCH₂), 2.62 – 2.53 (m, 2H, pyridine-NCH₂CH₂N), 2.52 – 2.42 (m, 2H, pyridine-NCH₂CH₂N), 2.35 – 2.22 (m, 2H, CCHCH₂ + CH(CH₃)₂), 1.87 – 1.63 (m, 6H, cyclohexane-3CH₂), 1.55 – 1.41 (m, phenyl-cyclohexane-CH₂CH₂), 1.29 (s, 3H, CCH₃CH₂), 1.22 (s, 3H, CCH₃COO), 1.21 (d, *J* = 2.5 Hz, 6H, CH(CH₃)₂). **¹³C NMR (126 MHz, CDCl₃)** δ 178.63, 159.79, 146.93, 145.83, 143.09, 143.06, 136.12, 136.10,

134.74, 127.00, 124.30, 124.06, 120.93, 66.70, 66.57, 65.26, 60.57, 60.49, 53.12, 48.61, 47.92, 44.97, 44.92, 38.01, 37.06, 36.74, 33.55, 30.23, 25.34, 24.10, 21.87, 18.68, 16.66.

¹⁹F NMR (376 MHz, CDCl₃) δ -61.39. **HRMS:** *m/z* [M+H]⁺ calcd for C₃₃H₄₄N₃O₃F₃Cl:622.3018; found:622.3013.

3-((4-*N*-4-fluorobenzylpiperazine) amino)-2-hydroxypropyl-1-dehydroabietic acid ester (2h)

A colorless oil liquid, yield 75.3%; **¹H NMR (400 MHz, CDCl₃)** δ 7.11 (dd, *J* = 8.4, 5.6 Hz, 2H, piperazine-NCH₂C(CH)₂(CH)₂CF), 7.01 (d, *J* = 8.4 Hz, 1H, DAA-phenyl-H), 6.87 – 6.80 (m, 3H, piperazine-NCH₂C(CH)₂(CH)₂CF + DAA-phenyl-1H), 6.72 (s, 1H, DAA-phenyl-H), 5.12 (s, 1H, OH), 4.03 (dd, *J* = 11.2, 3.6 Hz, 1/2H, 1/4COOCH₂CHCH₂), 3.97 – 3.88 (m, 1H, 1/2COOCH₂CHCH₂), 3.84 (dd, *J* = 11.4, 5.7 Hz, 1/2H, 1/4COOCH₂CHCH₂), 3.74 (m, 1H, COOCH₂CHCH₂), 2.78 – 2.69 (m, 2H, phenyl-cyclohexane-CH₂CH₂), 2.68 – 2.60 (m, 1H, 1/2COOCH₂CHCH₂), 2.51 (s, 1H, 1/2COOCH₂CHCH₂), 2.35 – 2.18 (m, 8H, piperazine-8H), 2.17 – 2.06 (m, 2H, CCHCH₂ + CH(CH₃)₂), 1.38 – 1.25 (m, 6H, cyclohexane-CH₂CH₂CH₂), 1.38 – 1.25 (m, 2H, phenyl-cyclohexane-CH₂), 1.12 (d, *J* = 9.2 Hz, 3H, CCH₃CH₂), 1.07 (s, 3H, CCH₃COO), 1.05 (s, 6H, CH(CH₃)₂). **¹³C NMR (101 MHz, CDCl₃)** δ 178.55, 163.25, 160.82, 146.88, 145.73, 134.70, 133.70, 130.68 (*d*, ¹*J*_{C-F} = 7.8), 126.93 (*d*, ²*J*_{C-F} = 2.3), 124.22, 123.97, 115.17, 114.96, 66.69, 66.55, 65.05, 62.16, 60.29, 60.22, 53.02, 47.82, 44.83, 37.95, 36.99, 36.67, 33.48, 30.15, 25.28, 24.03, 21.79, 18.61, 16.59. **¹⁹F NMR (376 MHz, CDCl₃)** δ -115.67. **HRMS:** *m/z* [M+H]⁺ calcd for C₃₄H₄₈N₂O₃F:551.3646; found:551.3639.

3-piperidine-2-hydroxypropyl-1-dehydroabietic acid ester (2i)

A yellowish solid, yield 81.6%, m. p. 61.7-62.9 °C; ^1H NMR (500 MHz, CDCl_3) δ 7.16 (d, $J = 8.1$ Hz, 1H, phenyl-H), 6.99 (d, $J = 7.6$ Hz, 1H, phenyl-H), 6.88 (s, 1H, phenyl-H), 4.19 – 3.97 (m, 2H, $\text{COOCH}_2\text{CHCH}_2$), 3.92 (s, 1H, $\text{COOCH}_2\text{CHCH}_2$), 3.00 – 2.85 (m, 2H, phenyl-cyclohexane- CH_2), 2.82 (m, 1H, $1/2 \text{COOCH}_2\text{CHCH}_2$), 2.60 (s, 1H, $1/2 \text{COOCH}_2\text{CHCH}_2$), 2.42 – 2.30 (m, 4H, piperidine- $\text{CH}_2\text{N}(\text{CH}_2)_2$), 2.30 – 2.19 (m, 2H, $\text{CCHCH}_2 + \text{CH}(\text{CH}_3)_2$), 1.89 – 1.63 (m, 6H, cyclohexane- $\text{CH}_2\text{CH}_2\text{CH}_2$), 1.55 (d, $J = 22.5$ Hz, 4H, piperidine- $\text{CH}_2\text{N}(\text{CH}_2\text{CH}_2)_2$), 1.47 (d, $J = 29.6$ Hz, 4H = 2H + 2H, phenyl-cyclohexane- $\text{CH}_2 + \text{piperidine-N}(\text{CH}_2\text{CH}_2)_2\text{CH}_2$), 1.27 (d, $J = 13.8$ Hz, 3H, CCH_3CH_2), 1.22 (s, 3H, CCH_3COO), 1.21 (s, 6H, $\text{CH}(\text{CH}_3)_2$). ^{13}C NMR (126 MHz, CDCl_3) δ 178.59, 146.96, 145.76, 134.81, 126.99, 124.29, 124.00, 66.87, 66.72, 64.93, 61.10, 61.03, 54.78, 47.87, 44.95, 44.90, 38.03, 37.06, 36.73, 33.56, 30.21, 26.02, 25.36, 24.18, 24.12, 21.86, 18.70, 16.66. HRMS: m/z $[\text{M}+\text{H}]^+$ calcd for $\text{C}_{28}\text{H}_{44}\text{NO}_3$:442.3316; found:442.3313.

3-(2-methyl) piperidine-2-hydroxypropyl-1-dehydroabietic acid ester (2j)

A white oil liquid, yield 49.6%; ^1H NMR (500 MHz, CDCl_3) δ 7.15 (d, $J = 8.0$ Hz, 1H, phenyl-H), 6.98 (d, $J = 8.0$ Hz, 1H, phenyl-H), 6.87 (s, 1H, phenyl-H), 4.17 – 3.97 (m, 2H, $\text{COOCH}_2\text{CHCH}_2$), 3.94 – 3.86 (m, 1H, $\text{COOCH}_2\text{CHCH}_2$), 3.86 – 3.67 (m, 1H, piperidine- NCHCH_3), 3.00 – 2.85 (m, 2H, phenyl-cyclohexane- CH_2), 2.84 – 2.64 (m, 2H, $\text{COOCH}_2\text{CHCH}_2$), 2.50 – 2.34 (m, 1H, piperidine- $1/2\text{CH}_2$), 2.35 – 2.22 (m, 2H, $\text{CCHCH}_2 + \text{CH}(\text{CH}_3)_2$), 2.20 – 2.04 (m, 1H, piperidine- $1/2\text{CH}_2$), 1.87 – 1.72 (m, 4H, piperidine- 2CH_2), 1.70 – 1.55 (m, 6H, cyclohexane- $\text{CH}_2\text{CH}_2\text{CH}_2$), 1.53 – 1.43 (m, 2H,

phenyl-cyclohexane-CH₂), 1.28 (s, 3H, CCH₃CH₂), 1.21 (s, 3H, CCH₃COO), 1.20 (s, 6H, CH(CH₃)₂), 1.05 – 0.99 (m, 3H, piperidine-NCHCH₃). **¹³C NMR (126 MHz, CDCl₃)** δ 178.58, 146.94, 145.75, 134.79, 126.99, 124.25, 123.99, 66.69, 66.01, 64.65, 57.00, 56.26, 55.24, 52.58, 47.86, 44.94, 38.05, 37.03, 36.76, 34.65, 33.56, 32.95, 30.18, 25.99, 25.30, 24.10, 23.79, 21.84, 18.68, 16.64. **HRMS:** *m/z* [M+H]⁺ calcd for C₂₉H₄₆NO₃:456.3472; found:456.3466.

3-(3-methyl) piperidine-2-hydroxypropyl-1-dehydroabietic acid ester (2k)

A colorless oil liquid, yield 68.4%; **¹H NMR (500 MHz, CDCl₃)** δ 7.16 (d, *J* = 8.0 Hz, 1H, phenyl-H), 6.99 (d, *J* = 7.5 Hz, 1H, phenyl-H), 6.87 (s, 1H, phenyl-H), 4.19 – 3.97 (m, 2H, COOCH₂CHCH₂), 3.94 (m, 1H, COOCH₂CHCH₂), 3.88 – 3.67 (m, 1H, piperidine-(CH₂)₂CHCH₃), 2.99 – 2.86 (m, 2H, phenyl-cyclohexane-CH₂), 2.85 – 2.56 (m, 2H, COOCH₂CHCH₂), 2.49 – 2.32 (m, 2H, piperidine-CH₂), 2.30 – 2.17 (m, 2H, CCH₃CH₂ + CH(CH₃)₂), 1.95 – 1.70 (m, 6H, piperidine-3CH₂), 1.69 – 1.51 (m, 6H, cyclohexane-CH₂CH₂CH₂), 1.51 – 1.37 (m, 2H, phenyl-cyclohexane-CH₂), 1.27 (d, *J* = 13.6 Hz, 3H, CCH₃CH₂), 1.22 (s, 3H, CCH₃COO), 1.21 (d, *J* = 15.0 Hz, 6H, CH(CH₃)₂), 0.85 (d, *J* = 6.5 Hz, 3H, piperidine-(CH₂)₂CHCH₃). **¹³C NMR (126 MHz, CDCl₃)** δ 178.61, 147.10, 145.78, 134.80, 127.00, 124.30, 124.01, 66.73, 64.97, 64.91, 60.57, 55.65, 52.83, 47.88, 44.90, 38.01, 37.06, 36.73, 33.56, 32.69, 31.09, 30.21, 25.37, 24.11, 21.86, 19.63, 19.58, 18.69, 16.65. **HRMS:** *m/z* [M+H]⁺ calcd for C₂₉H₄₆NO₃:456.3472; found:456.3468.

3-(4-methyl) piperidine-2-hydroxypropyl-1-dehydroabietic acid ester (2l)

A yellowish solid, yield 94.9%, m. p. 58.9-60.2 °C; **¹H NMR (500 MHz, CDCl₃)** δ

7.16 (d, $J = 8.0$ Hz, 1H, phenyl-H), 6.99 (d, $J = 8.0$ Hz, 1H, phenyl-H), 6.87 (s, 1H, phenyl-H), 5.05 – 4.97 (m, 1H, OH), 4.20 – 3.96 (m, 2H, COOCH₂CHCH₂), 3.91 (td, $J = 9.5, 4.9$ Hz, 1H, COOCH₂CHCH₂), 2.96 – 2.86 (m, 2H, phenyl-cyclohexane-CH₂CH₂), 2.85 – 2.73 (m, 2H, COOCH₂CHCH₂), 2.40 – 2.31 (m, 2H, piperidine-CH₂), 2.30 – 2.23 (m, 2H, CCHCH₂ + CH(CH₃)₂), 2.04 – 1.90 (m, 1H, piperidine-(CH₂)₂CHCH₃), 1.85 – 1.58 (m, 8H = 6H+2H, cyclohexane-CH₂CH₂CH₂ + piperidine-CH₂), 1.55 – 1.40 (m, 2H, phenyl-cyclohexane-CH₂), 1.28 (d, $J = 14.0$ Hz, 3H, CCH₃CH₂), 1.22 (s, 3H, CCH₃COO), 1.21 (s, 6H, CH(CH₃)₂), 0.91 (d, $J = 6.4$ Hz, 3H, piperidine-(CH₂)₂CHCH₃). **¹³C NMR (126 MHz, CDCl₃)** δ 178.60, 146.95, 145.76, 134.81, 127.00, 124.29, 124.00, 67.10, 66.88, 66.73, 65.04, 60.71, 55.74, 52.65, 47.87, 44.90, 38.02, 37.05, 36.72, 34.51, 34.17, 33.56, 30.66, 30.21, 25.36, 24.11, 21.92, 18.69, 16.65. **HRMS:** m/z [M+H]⁺ calcd for C₂₉H₄₆NO₃:456.3472; found:456.3467.

3-(4-Bromi) piperidine-2-hydroxypropyl-1-dehydroabietic acid ester (2m)

A white solid, yield 40.1%, m. p. 83.6-85.1 °C; **¹H NMR (500 MHz, CDCl₃)** δ 7.17 (d, $J = 8.0$ Hz, 1H, phenyl-H), 7.00 (d, $J = 8.0$ Hz, 1H, phenyl-H), 6.88 (s, 1H, phenyl-H), 4.27 – 3.97 (m, 2H, COOCH₂CHCH₂), 3.90 (m, 1H, COOCH₂CHCH₂), 3.36 (s, 1H, CH-Br), 2.95 – 2.77 (m, 4H, phenyl-cyclohexane-CH₂ + COOCH₂CHCH₂), 2.73 – 2.44 (m, 2H, piperidine-CH₂NCH₂CH₂), 2.43 – 2.33 (m, 2H, piperidine-CH₂NCH₂CH₂), 2.32 – 2.24 (m, 2H, CCHCH₂ + CH(CH₃)₂), 2.20 – 2.10 (m, 2H, piperidine-CH₂NCH₂CH₂), 2.07 – 1.95 (m, 2H, piperidine-CH₂NCH₂CH), 1.90 – 1.58 (m, 6H, cyclohexane-CH₂CH₂CH₂), 1.55 – 1.37 (m, 2H, phenyl-cyclohexane-CH₂), 1.29 – 1.25 (s, 3H, CCH₃CH₂), 1.22 (s, 3H, CCH₃COO), 1.21 (s, 6H, CH(CH₃)₂). **¹³C NMR (126**

MHz, CDCl₃) δ 178.62, 146.93, 145.82, 134.75, 127.01, 124.31, 124.05, 66.70, 66.57, 65.31, 60.37, 60.30, 47.90, 44.96, 44.91, 38.02, 37.06, 36.74, 36.20, 33.56, 30.22, 25.36, 24.13, 21.87, 18.69, 16.67. **HRMS:** m/z $[M+H]^+$ calcd for C₂₈H₄₃NO₃Br:520.2421; found:520.2419.

3-(4-chloro) piperidine-2-hydroxypropyl-1-dehydroabietic acid ester (2n)

A white solid, yield 44.7%, m. p. 99.2-100.5 °C; **¹H NMR (500 MHz, CDCl₃)** δ 7.16 (d, J = 8.5 Hz, 1H, phenyl-H), 6.99 (d, J = 8.0 Hz, 1H, phenyl-H), 6.87 (s, 1H, phenyl-H), 4.16 (dd, J = 11.5, 4.0 Hz, 1/2H, 1/2CH-Br), 4.07 (ddd, J = 19.5, 11.5, 4.0 Hz, 2H, COOCH₂CHCH₂), 3.99 (dd, J = 11.5, 6.0 Hz, 1/2H, 1/2CH-Br), 3.91 – 3.86 (m, 1H, COOCH₂CHCH₂), 2.94 – 2.77 (m, 4H, phenyl-cyclohexane-CH₂ + COOCH₂CHCH₂), 2.73 – 2.62 (m, 1H, piperidine-1/2CH₂), 2.54 – 2.45 (m, 1H, piperidine-1/2CH₂), 2.41 – 2.34 (m, 2H, cyclohexane-CH₂), 2.32 – 2.20 (m, 2H, CCHCH₂ + CH(CH₃)₂), 2.15 – 2.03 (m, 2H, piperidine-CH₂NCH₂CH₂), 1.95 – 1.85 (m, 2H, piperidine-CH₂NCH₂CH₂), 1.80 – 1.55 (m, 6H, cyclohexane-CH₂CH₂CH₂), 1.55 – 1.40 (m, 2H, phenyl-cyclohexane-CH₂), 1.28 – 1.24 (m, 3H, CCH₃CH₂), 1.21 (s, 3H, CCH₃COO), 1.20 (s, 6H, CH(CH₃)₂). **¹³C NMR (126 MHz, CDCl₃)** δ 178.63, 146.98, 145.81, 134.75, 126.98, 124.29, 124.04, 66.69, 66.56, 65.30, 60.29, 60.22, 56.85, 50.98, 47.90, 44.95, 44.89, 38.00, 37.05, 36.72, 35.43, 33.54, 30.21, 25.34, 24.10, 21.85, 18.67, 16.64. **HRMS:** m/z $[M+H]^+$ calcd for C₂₈H₄₃NO₃Cl:476.2926; found:476.2925.

3-(4-hydroxyl) piperidine-2-hydroxypropyl-1-dehydroabietic acid ester (2o)

A colorless oil liquid, yield 41.7%; **¹H NMR (500 MHz, CDCl₃)** δ 7.15 (d, J = 8.0 Hz, 1H, phenyl-H), 6.98 (d, J = 8.0 Hz, 1H, phenyl-H), 6.86 (s, 1H, phenyl-H), 4.16 (dd,

1/2H, 1/4COOCH₂CHCH₂), 4.07 (dd, 1H, 1/2COOCH₂CHCH₂), 4.01 – 3.95 (dd, 1/2H, 1/4COOCH₂CHCH₂), 3.93 – 3.85 (m, 1H, COOCH₂CHCH₂), 3.71 (s, 1H, piperidine-CH₂OH), 2.94 – 2.77 (m, 4H, phenyl-cyclohexane-CH₂ + COOCH₂CHCH₂), 2.68 – 2.58 (m, 1H, piperidine-1/2CH₂), 2.44 – 2.35 (m, 2H, phenyl-cyclohexane-CH₂), 2.32 – 2.20 (m, 2H, CCH₂CH₂ + CH(CH₃)₂), 2.16 (s, 1H, piperidine-1/2CH₂), 1.92 – 1.75 (m, 4H, piperidine-2CH₂), 1.74 – 1.50 (m, 6H, cyclohexane-CH₂CH₂CH₂), 1.48 – 1.38 (m, 2H, phenyl-cyclohexane-CH₂), 1.26 (d, *J* = 12.2 Hz, 3H, CCH₃CH₂), 1.21 (s, 3H, CCH₃COO), 1.20 (s, 6H, CH(CH₃)₂). ¹³C NMR (126 MHz, CDCl₃) δ 178.68, 146.93, 145.81, 134.77, 126.99, 124.29, 124.02, 66.75, 66.62, 65.29, 60.28, 60.21, 50.48, 47.89, 44.94, 44.89, 37.99, 37.04, 36.72, 34.51, 34.34, 33.54, 30.18, 25.34, 24.10, 21.84, 18.67, 16.64. HRMS: *m/z* [M+H]⁺ calcd for C₂₈H₄₄NO₄:458.3265; found:458.3260.

3-*N*-morpholine-2-hydroxypropyl-1-dehydroabietic acid ester (2p)

A yellowish solid, yield 60.7%, m. p.74.8-75.9 °C; ¹H NMR (500 MHz, CDCl₃) δ 7.16 (d, *J* = 8.0 Hz, phenyl-H), 6.99 (d, *J* = 8.0 Hz, phenyl-H), 6.87 (s, 1H, phenyl-H), 4.18 (dd, *J* = 11.5, 3.5 Hz, 1/2H, 1/4COOCH₂CHCH₂), 4.13 – 4.04 (m, 1H, 1/2COOCH₂CHCH₂), 4.00 (dd, *J* = 11.4, 5.7 Hz, 1/2H, 1/4COOCH₂CHCH₂), 3.96 – 3.89 (m, 1H, COOCH₂CHCH₂), 3.75 – 3.65 (m, 4H, morpholine-N(CH₂)₂(CH₂)₂), 2.90 – 2.85 (m, 2H, phenyl-cyclohexane-CH₂), 2.81 (dt, *J* = 13.8, 7.0 Hz, 1H, 1/2COOCH₂CHCH₂), 2.62 (dd, *J* = 10.4, 5.5 Hz, 1H, 1/2COOCH₂CHCH₂), 2.45 – 2.35 (m, 4H, morpholine-N(CH₂)₂(CH₂)₂), 2.27 (dd, *J* = 23.5, 12.0 Hz, 2H, CCH₂CH₂ + CH(CH₃)₂), 1.87 – 1.63 ((m, 6H, cyclohexane-CH₂CH₂CH₂), 1.53 – 1.39 (m, 2H, phenyl-cyclohexane-CH₂), 1.27 (s, 3H, CCH₃CH₂), 1.21 (s, 3H, CCH₃COO), 1.20 (s,

6H, CH(CH₃)₂). ¹³C NMR (126 MHz, CDCl₃) δ 178.63, 146.91, 145.83, 134.73, 126.98, 124.30, 124.05, 67.03, 66.66, 66.54, 65.04, 60.99, 60.91, 53.75, 47.90, 44.94, 38.00, 37.05, 36.73, 33.55, 30.19, 25.34, 24.10, 21.85, 18.67, 16.65. HRMS: *m/z* [M+H]⁺ calcd for C₂₇H₄₂NO₄:444.3108; found:444.3104.




Figure S1. ¹H NMR Spectrum (DMSO-*d*₆, 500 MHz) of DAA.




Figure S2. ¹³C NMR Spectrum (CDCl₃, 126 MHz) of DAA.




Figure S3. ¹H NMR Spectrum (CDCl₃, 400 MHz) of 1.




Figure S4. ¹³C NMR Spectrum (CDCl₃, 101 MHz) of 1.




Figure S5. ¹H NMR Spectrum (CDCl₃, 500 MHz) of 2a.




Figure S6. ^{13}C NMR Spectrum (CDCl_3 , 126 MHz) of 2a.




Figure S7. HRMS Spectrum of 2a.




Figure S8. ¹H NMR Spectrum (CDCl₃, 400 MHz) of 2b.




Figure S9. ¹³C NMR Spectrum (CDCl₃, 101 MHz) of 2b.




Figure S10. HRMS Spectrum of 2b.




Figure S11. ¹H NMR Spectrum (CDCl₃, 500 MHz) of 2c.




Figure S12. ^{13}C NMR Spectrum (CDCl_3 , 126 MHz) of 2c.




Figure S13. HRMS Spectrum of 2c.




Figure S14. ¹H NMR Spectrum (CDCl₃, 400 MHz) of 2d.




Figure S15. ¹³C NMR Spectrum (CDCl₃, 101 MHz) of 2d.




Figure S16. HRMS Spectrum of 2d.




Figure S17. ¹H NMR Spectrum (CDCl₃, 500 MHz) of 2e.




Figure S18. ¹³C NMR Spectrum (CDCl₃, 126 MHz) of 2e.




Figure S19. ¹⁹F NMR Spectrum (DMSO-*d*₆, 376 MHz) of 2e.

19 #177 RT: 1.71 AV: 1 NL: 2.59E8
T: FTMS + p ESI Full ms [100.0000-1300.0000]




Figure S20. HRMS Spectrum of 2e.




Figure S21. ¹H NMR Spectrum (DMSO-*d*₆, 400 MHz) of 2f.




Figure S22. ¹³C NMR Spectrum (DMSO-*d*₆, 101 MHz) of 2f.




Figure S23. ¹⁹F NMR Spectrum (DMSO-*d*₆, 376 MHz) of 2f.

Mass spectrum of compound 10. The x-axis represents the mass-to-charge ratio (m/z) from 150 to 850. The y-axis represents relative intensity from 22 to 64. The base peak is at m/z 332.2922. Other significant peaks are labeled at m/z 136.0757, 172.0943, 223.0940, 256.2633, 282.2789, 304.2606, 374.3026, 407.7925, 453.3432, 475.3253, 520.8766, 537.3485, 566.4274, 588.4094, 619.6136, 675.6760, 701.4932, 743.6246, 792.5954, 814.5773, and 834.2388. The peak at m/z 537.3485 is identified as $C_{23}H_{46}O_3N_2F$ with a calculated mass of 537.3487 and an observed mass of -0.3484 ppm.

¹H NMR spectrum (CDCl₃) of compound 10a. The x-axis represents the chemical shift in ppm, ranging from 10.0 to -1.5. The spectrum shows several peaks with corresponding integration values. A list of chemical shifts (delta) is provided on the right side of the plot.

Chemical shifts (delta): 8.381, 7.751, 7.747, 7.173, 7.157, 7.003, 6.987, 6.876, 5.276, 4.196, 4.126, 4.118, 4.113, 4.102, 4.039, 3.980, 3.971, 3.963, 3.523, 2.889, 2.874, 2.825, 2.811, 2.798, 2.787, 2.778, 2.584, 2.576, 2.565, 2.555, 2.545, 2.483, 2.476, 2.463, 2.454, 2.311, 2.284, 2.279, 2.274, 2.269, 2.253, 2.248, 1.797, 1.778, 1.755, 1.711, 1.671, 1.655, 1.504, 1.458, 1.288, 1.217, 1.208, 1.203.

Integration values (from left to right): 1.17, 1.15, 1.00, 1.00, 1.00, 0.67, 2.34, 1.16, 4.48, 2.00, 2.44, 2.47, 2.46, 2.20, 6.42, 2.40, 3.00, 3.17, 6.33.

Figure S25. ¹H NMR Spectrum (CDCl₃, 500 MHz) of 2g.




Figure S26. ^{13}C NMR Spectrum (CDCl_3 , 126 MHz) of 2g.




Figure S27. ^{19}F NMR Spectrum (CDCl_3 , 376 MHz) of 2g.




Figure S28. HRMS Spectrum of 2g.




Figure S29. ¹H NMR Spectrum (CDCl₃, 400 MHz) of 2h.




Figure S30. ¹³C NMR Spectrum (CDCl₃, 101 MHz) of 2h.




Figure S31. ¹⁹F NMR Spectrum (CDCl₃, 376 MHz) of 2h.




Figure S32. HRMS Spectrum of 2h.




Figure S33. ^1H NMR Spectrum (CDCl₃, 500 MHz) of 2i.




Figure S34. ^{13}C NMR Spectrum (CDCl₃, 126 MHz) of 2i.




Figure S35. HRMS Spectrum of 2i.




Figure S36. ¹H NMR Spectrum (CDCl₃, 500 MHz) of 2j.




Figure S37. ¹³C NMR Spectrum (CDCl₃, 126 MHz) of 2j.




Figure S38. HRMS Spectrum of 2j.




Figure S39. ¹H NMR Spectrum (CDCl₃, 500 MHz) of 2k.




Figure S40. ^{13}C NMR Spectrum (CDCl_3 , 126 MHz) of 2k.




Figure S41. HRMS Spectrum of 2k.




Figure S42. ¹H NMR Spectrum (CDCl₃, 500 MHz) of 2l.




Figure S43. ¹³C NMR Spectrum (CDCl₃, 126 MHz) of 2l.




Figure S44. HRMS Spectrum of 2l.




Figure S45. ¹H NMR Spectrum (CDCl₃, 500 MHz) of 2m.




Figure S46. ^{13}C NMR Spectrum (CDCl_3 , 126 MHz) of 2m.

27.8147 RT: 1.42 AV: 1 NL: 4.20E6
T: FTMS + p ESI Full ms [100.0000-1300.0000]




Figure S47. HRMS Spectrum of 2m.




Figure S48. ¹H NMR Spectrum (CDCl₃, 500 MHz) of 2n.




Figure S49. ¹³C NMR Spectrum (CDCl₃, 126 MHz) of 2n.

28 #185 RT: 1.78 AV: 1 NL: 2.48E8
T: FTMS + p ESI Full ms [100.0000-1300.0000]




Figure S50. HRMS Spectrum of 2n.




Figure S51. ¹H NMR Spectrum (CDCl₃, 500 MHz) of 2o.




Figure S52. ¹³C NMR Spectrum (CDCl₃, 126 MHz) of 2o.




Figure S53. HRMS Spectrum of 2o.




Figure S54. ¹H NMR Spectrum (CDCl₃, 500 MHz) of 2p.




Figure S55. ¹³C NMR Spectrum (CDCl₃, 126 MHz) of 2p.




Figure S56. HRMS Spectrum of 2p.

3. Figure S57. The physicochemical properties of resulting compounds.

